Top

Published in:

Open Access 01-12-2017 | Research article

Cross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya

Authors: Natalie R. Pritchett, Stephen L. Burgert, Gwen A. Murphy, John D. Brockman, Russell E. White, Justus Lando, Robert Chepkwony, Mark D. Topazian, Christian C. Abnet, Sanford M. Dawsey, Michael M. Mwachiro

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

Low serum selenium status has been associated with increased risk of esophageal squamous cell carcinoma (ESCC). East Africa is a region of high ESCC incidence and is known to have low soil selenium levels, but this association has not previously been evaluated. In this study we assessed the association of serum selenium concentration and the prevalence of esophageal squamous dysplasia (ESD), the precursor lesion of ESCC, in a cross-sectional study of subjects from Bomet, Kenya.

Methods

294 asymptomatic adult residents of Bomet, Kenya completed questionnaires and underwent endoscopy with Lugol’s iodine staining and biopsy for detection of ESD. Serum selenium concentrations were measured by instrumental neutron activation analysis. Odds ratios (OR) and confidence intervals (95% CI) for associations between serum selenium and ESD were calculated using unconditional logistic regression.

Results

The mean serum selenium concentration was 85.5 (±28.3) μg/L. Forty-two ESD cases were identified (14% of those screened), including 5 (12%) in selenium quartile 1 (Q1), 5 (12%) in Q2, 15 (36%) in Q3, and 17 (40%) in Q4. Higher serum selenium was associated with prevalence of ESD (Q4 vs Q1: OR: 3.03; 95% CI: 1.05–8.74) and this association remained after adjusting for potential confounders (Q4 vs Q1: OR: 3.87; 95% CI: 1.06–14.19).

Conclusion

This is the first study to evaluate the association of serum selenium concentration and esophageal squamous dysplasia in an African population at high risk for ESCC. We found a positive association between higher serum selenium concentration and prevalence of ESD, an association contrary to our original hypothesis. Further work is needed to better understand the role of selenium in the etiology of ESCC in this region, and to develop effective ESCC prevention and control strategies.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.29210.CrossRefPubMed

Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52. doi:10.1056/NEJMra035010.CrossRefPubMed

Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer—an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230–44. doi:10.1038/nrgastro.2012.236.CrossRefPubMed

Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. The incidence of oesophageal cancer in eastern Africa: identification of a new geographic hot spot? Cancer Epidemiol. 2015;39:143–9. doi:10.1016/j.canep.2015.01.001 PMC4470609.CrossRefPubMedPubMedCentral

Gabel JV, Chamberlain RM, Ngoma T, Mwaiselage J, Schmid KK, Kahesa C, Soliman AS. Clinical and epidemiologic variations of esophageal cancer in Tanzania. World J Gastrointest Oncol. 2016;8:314–20. doi:10.4251/wjgo.v8.i3.314 PMC4789617.CrossRefPubMedPubMedCentral

Kayamba V, Sinkala E, Mwanamakondo S, Soko R, Kawimbe B, Amadi B, Zulu I, Nzaisenga JB, Banda T, Mumbwe C, et al. Trends in upper gastrointestinal diagnosis over four decades in Lusaka, Zambia: a retrospective analysis of endoscopic findings. BMC Gastroenterol. 2015;15:127. doi:10.1186/s12876-015-0353-8 4596361.CrossRefPubMedPubMedCentral

Ahmed N, Cook P. The incidence of cancer of the oesophagus in West Kenya. Br J Cancer. 1969;23:302–122008286.CrossRefPubMedPubMedCentral

McCormack VA, Menya D, Munishi MO, Dzamalala C, Gasmelseed N, Leon Roux M, Assefa M, Osano O, Watts M, Mwasamwaja AO, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: a review of setting-specific exposures to known and putative risk factors. Int J Cancer. 2017;140:259–71. doi:10.1002/ijc.30292.CrossRefPubMed

Burkitt DP. Distribution of cancer in Africa. Proc R Soc Med. 1973;66:312–4. PMC1644893PubMedPubMedCentral

10.

Korir A, Okerosi N, Ronoh V, Mutuma G, Parkin M. Incidence of cancer in Nairobi, Kenya (2004-2008). Int J Cancer. 2015;137:2053–9. doi:10.1002/ijc.29674.CrossRefPubMed

11.

Parker RK, Dawsey SM, Abnet CC, White RE. Frequent occurrence of esophageal cancer in young people in western Kenya. Dis Esophagus. 2010;23:128–35. doi:10.1111/j.1442-2050.2009.00977.x PMC3505035.CrossRefPubMed

12.

Castellsague X, Munoz N, De Stefani E, Victora CG, Castelletto R, Rolon PA, Quintana MJ. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer. 1999;82:657–64.CrossRefPubMed

13.

Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Abnet CC, Shakeri R, Pourshams A, Marjani HA, Nouraie M, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008;98:1857–63. doi:10.1038/sj.bjc.6604369 PMC2410115.CrossRefPubMedPubMedCentral

14.

Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, Fraumeni JF Jr, Blot WJ, Dong ZW, Taylor PR. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst. 2000;92:1753–63.CrossRefPubMed

15.

Wei WQ, Abnet CC, Qiao YL, Dawsey SM, Dong ZW, Sun XD, Fan JH, Gunter EW, Taylor PR, Mark SD. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr. 2004;79:80–5.PubMed

16.

Knekt P, Aromaa A, Maatela J, Alfthan G, Aaran RK, Hakama M, Hakulinen T, Peto R, Teppo L. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst. 1990;82:864–8.CrossRefPubMed

17.

Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 2010;138:1704–13. doi:10.1053/j.gastro.2009.12.004.CrossRefPubMed

18.

Rayman MP. Selenium and human health. Lancet. 2012;379:1256–68. doi:10.1016/S0140-6736(11)61452-9.CrossRefPubMed

19.

Boosalis MG. The role of selenium in chronic disease. Nutr Clin Pract. 2008;23:152–60. doi:10.1177/0884533608314532.CrossRefPubMed

20.

Weber CL, Matthews HS. Food-miles and the relative climate impacts of food choices in the United States. Environ Sci Technol. 2008;42:3508–13.CrossRefPubMed

21.

Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids (vol 100, pg 638, 2000). J Am Diet Assoc. 2000;100:1008–9.

22.

Combs GF Jr. Biomarkers of selenium status. Nutrients. 2015;7:2209–36. doi:10.3390/nu7042209 PMC4425141.CrossRefPubMedPubMedCentral

23.

Thomson CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr. 2004;58:391–402. doi:10.1038/sj.ejcn.1601800.CrossRefPubMed

24.

Duffield AJ, Thomson CD, Hill KE, Williams S. An estimation of selenium requirements for new Zealanders. Am J Clin Nutr. 1999;70:896–903.PubMed

25.

Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, Wang L, Byrne DW, Burk RF. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr. 2010;92:525–31. doi:10.3945/ajcn.2010.29642 PMC2921536.CrossRefPubMedPubMedCentral

26.

Joy EJ, Ander EL, Young SD, Black CR, Watts MJ, Chilimba AD, Chilima B, Siyame EW, Kalimbira AA, Hurst R, et al. Dietary mineral supplies in Africa. Physiol Plant. 2014;151:208–29. doi:10.1111/ppl.12144 4235459.CrossRefPubMedPubMedCentral

27.

Combs GF Jr. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr. 2005;135:343–7.PubMed

28.

Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85:1483–92.CrossRefPubMed

29.

Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, Johnson LL, Gail MH, Dong ZW, Yu B, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian general population nutrition intervention trial. J Natl Cancer Inst. 2009;101:507–18. doi:10.1093/jnci/djp037 2664089.CrossRefPubMedPubMedCentral

30.

Taylor PR, Abnet CC, Dawsey SM. Squamous dysplasia--the precursor lesion for esophageal squamous cell carcinoma. Cancer Epidemiol Biomark Prev. 2013;22:540–52. doi:10.1158/1055-9965.EPI-12-1347 PMC3681095.CrossRef

31.

Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005;129:863–73. doi:10.1053/j.gastro.2005.06.024.CrossRefPubMed

32.

Mwachiro MM, Burgert SL, Lando J, Chepkwony R, Bett C, Bosire C, Abnet CC, Githanga J, Waweru W, Giffen CA, et al. Esophageal Squamous dysplasia is common in asymptomatic Kenyans: a prospective, community-based, cross-sectional study. Am J Gastroenterol. 2016; doi:10.1038/ajg.2016.26.

33.

Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, Li JY, Blot WJ, Li B, Taylor PR. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer. 1994;74:1686–92.CrossRefPubMed

34.

Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey SM. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187–92. doi:10.1136/gut.2004.046631 PMC1774842.CrossRefPubMedPubMedCentral

35.

Dawsey SM, Lewin KJ, Liu FS, Wang GQ, Shen Q. Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients. Cancer. 1994;73:2027–37.CrossRefPubMed

36.

Schatzkin A. Problems with using biomarkers as surrogate end points for cancer: a cautionary tale. Recent Results Cancer Res. 2005;166:89–98.CrossRefPubMed

37.

Gordis L. Epidemiology, 5th edition pp 332–334. Amsterdam: Elsevier; 2013.

38.

Vinceti M, Dennert G, Crespi CM, Zwahlen M, Brinkman M, Zeegers MP, Horneber M, D'Amico R, Del Giovane C. Selenium for preventing cancer. Cochrane Database Syst Rev. 2014;3:CD005195. doi:10.1002/14651858.CD005195 PMC4441528.PubMedCentral

39.

Chen X, Mikhail SS, Ding YW, Yang G, Bondoc F, Yang CS. Effects of vitamin E and selenium supplementation on esophageal adenocarcinogenesis in a surgical model with rats. Carcinogenesis. 2000;21:1531–6.CrossRefPubMed

40.

Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the nutritional prevention of cancer trial. Cancer Epidemiol Biomark Prev. 2002;11:630–9.

41.

Laclaustra M, Stranges S, Navas-Acien A, Ordovas JM, Guallar E. Serum selenium and serum lipids in US adults: National Health and nutrition examination survey (NHANES) 2003-2004. Atherosclerosis. 2010;210:643–8. doi:10.1016/j.atherosclerosis.2010.01.005 PMC2878899.CrossRefPubMedPubMedCentral

42.

Chilimba AD, Young SD, Black CR, Rogerson KB, Ander EL, Watts MJ, Lammel J, Broadley MR. Maize grain and soil surveys reveal suboptimal dietary selenium intake is widespread in Malawi. Sci Rep. 2011;1:72. doi:10.1038/srep00072 3216559.CrossRefPubMedPubMedCentral

Title: Cross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya
Authors: Natalie R. Pritchett
Stephen L. Burgert
Gwen A. Murphy
John D. Brockman
Russell E. White
Justus Lando
Robert Chepkwony
Mark D. Topazian
Christian C. Abnet
Sanford M. Dawsey
Michael M. Mwachiro
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3837-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Study protocol of the TIRED study: a randomised controlled trial comparing either graded exercise therapy for severe fatigue or cognitive behaviour therapy with usual care in patients with incurable cancer

Respiratory-gated (4D) contrast-enhanced FDG PET-CT for radiotherapy planning of lower oesophageal carcinoma: feasibility and impact on planning target volume

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection

Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer